Diagnostics

Diagnostics
Regulatory Science

Cellectar's iopofosine I 131 shows durable WM responses at 12 months

Phase 2b CLOVER WaM data show 83.6% ORR and 17.8-month median response duration, strengthening the case for accelerated FDA approval.
Phase 2b CLOVER WaM data show 83.6% ORR and 17.8-month median response duration, strengthening the case for accelerated FDA approval.
The Biotech Times Editorial Team  · 
Bioinformatics
Diagnostics
Digital Health

Alzai Health files IPO prospectus on TSXV to raise up to C$4m

The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at
The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health
Regulatory Science

ESO EMS Index: one in five patients accounts for 44% of 911 calls

ESO's 2026 EMS Index, drawing on 17.3 million records, reveals repeat callers and persistent obstetric care gaps as key system pressures.
ESO's 2026 EMS Index, drawing on 17.3 million records, reveals repeat callers and persistent obstetric care gaps as key system pressures.
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health

Ali Sheneamer Chief Business Development Officer at Bupa Arabia

Ali Sheneamer, Chief Business Development Officer at Bupa Arabia, introduced the Bupa Care Connect product, a healthcare solution aimed at improving patient care

Ali Sheneamer, Chief Business Development Officer at Bupa Arabia, introduced the Bupa Care Connect product, a digital-first healthcare solution aimed at improving patient care through connected services.

The Biotech Times Editorial Team  · 
Subscribe to Diagnostics